Clinical trials: Metastases
Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks
Systemic sclerosis (SSc) is a rare autoimmune disease in which many patients experience Raynaud's phenomenon (RP) - painful episodes where commonly fingers or toes change color and become painful, numb, or tingly, usually…
- Trial name
- RE-WARM (NCT07748000)
- Testing
- LIQ861 (treprostinil) inhalation powder - Dose Titration Arm, LIQ861 (treprostinil) inhalation powder - fixed dose arm
- Volunteers
- 75 people
- Sponsor
- Liquidia Technologies, Inc.
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
- Conditions
- Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease
- Trial name
- NCT06329401
- Testing
- AP01
- Where
- 154 sites in United States, Argentina and 12 more
- Volunteers
- 398 people
- Sponsor
- Avalyn Pharma Inc.
Neoplasms, Solid Tumors
Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors
This is a Phase 1 dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of BMS-754807 in patients with advanced or metastatic solid tumors.
- Conditions
- Neoplasms, Solid Tumors, Metastases
- Trial name
- NCT00569036
- Testing
- BMS-754807
- Where
- 5 sites in Australia
- Volunteers
- 63 people
- Sponsor
- Bristol-Myers Squibb
Brain Metastases
RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases
The purpose of this study is to determine whether RTA 744 is effective in the treatment of breast cancer that has metastasized to the brain.
- Trial name
- NCT00538343
- Testing
- berubicin hydrochloride (RTA 744)
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- Biogen
Breast Neoplasms
Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
The objective of this study was to assess efficacy and safety of radium-223 dichloride in subjects with human epidermal growth factor receptor 2 negative (HER2 negative) hormone receptor positive breast cancer with bone…
- Trial name
- NCT02258464
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Background hormonal therapy
- Where
- 71 sites in United States, Austria and 18 more
- Volunteers
- 99 people
- Sponsor
- Bayer
Insomnia, Secondary, Sleep Disturbance
Robustness and Usability of the Dreem 3 System for at Home Sleep Monitoring in an Insomnia Population.
There is an unmet medical need for monitoring sleep for multiple nights in a patient's home, without the inconvenience of traveling and staying overnight in a medical center, and without the need for a technician to set up a…
- Conditions
- Insomnia, Secondary, Sleep Disturbance, Sleep, Sleep Initiation and Maintenance Disorders
- Trial name
- NCT05611099
- Testing
- Dreem 3 System vs WatchPAT One, Usability Questionnaire
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Dreem
Breast Cancer, Prostate Cancer
Prospective PRO/QoL Registry for Patients With Bone Metastases of Breast or Prostate Cancer
Evaluation of patient reported outcomes (PRO) / QoL regarding typical ailments in real-life patients with bone metastases treated with osteoprotective agents.
- Conditions
- Breast Cancer, Prostate Cancer, Bone Metastases
- Trial name
- PROBone (NCT02410044)
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- iOMEDICO AG
Complications of Diabetes Mellitus, Diabetes Mellitus
Effect of Diacerein in the Metabolic Control of Patients With DM Type 2 and Secondary Failure to Metformin
Considering that, Diacerein is on the market for 16 years being used continuously in elderly patients with osteoarthritis without experience significant side effects, and considering the anti-hyperglycemic effect and the…
- Conditions
- Complications of Diabetes Mellitus, Diabetes Mellitus, Diabetes Mellitus, Type 2
- Trial name
- NCT03208309
- Testing
- Diacerein
- Where
- 3 sites in Brazil
- Volunteers
- 40 people
- Sponsor
- ANS Pharma
Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.
- Trial name
- KRYSTAL-12 (NCT04685135)
- Testing
- MRTX849, Docetaxel
- Where
- 380 sites in United States, Australia and 22 more
- Volunteers
- 453 people
- Sponsor
- Mirati Therapeutics Inc.
Diabetic Macular Edema
Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus
The purpose of this study is to demonstrate that two investigational treatment regimens have the potential to result in a superior visual acuity improvement as compared to a ranibizumab pro re nata (PRN=as needed) treatment…
- Trial name
- RETAIN (NCT01171976)
- Testing
- Ranibizumab
- Where
- 68 sites in Belgium, Czechia and 11 more
- Volunteers
- 373 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor, Adult, Advanced Solid Tumor
A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors
This is a Phase 1/1b open-label, dose-escalation, and cohort expansion study with BID (tablet) oral dose of MPT-0118 in subjects with advanced or metastatic refractory solid tumors.
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer
- Trial name
- NCT04859777
- Testing
- MPT-0118, MPT-0118 + pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 70 people
- Sponsor
- Monopteros Therapeutics Inc.
NSCLC Brain Metastasis
Tumor Treating Fields (TTF) in Combination with Stereotactic Radiosurgery(SRS) for Brain Metastases from Non-small Cell Lung Cancer.
This is a randomized, controlled, open-label, phase III trials. The main purpose of this study is to evaluate the effectiveness and safety of tumor treating felds (TTF) combined with stereotactic radiosurgery (SRS) in the…
- Trial name
- NCT06716775
- Testing
- Tumor treating felds (TTF), Best Standard of Care
- Volunteers
- 200 people
- Sponsor
- Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Endometrial Neoplasms
A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer
This study will investigate the individual safety and efficacy of two dual PI3K/mTOR inhibitors in patients with recurrent endometrial cancer.
- Trial name
- NCT01420081
- Testing
- PF-05212384
- Where
- 51 sites in United States, Australia and 6 more
- Volunteers
- 67 people
- Sponsor
- Pfizer
Advanced Pancreatic Cancer
Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer
A prospective, open, one-arm clinical study to evaluate the efficacy and safety of jinyouli in the first-line treatment of advanced pancreatic cancer with albumin paclitaxel combined with S-1.Chemotherapy regimen: (1)…
- Trial name
- NCT04239001
- Testing
- PEG-rhG-CSF
- Where
- China
- Volunteers
- 20 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Breast Neoplasms, Neoplasm Metastasis
Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
This study will look at different dose levels and regimens of everolimus combined with weekly trastuzumab and vinorelbine therapy in patients with HER-2 overexpressing metastatic breast cancer.
- Trial name
- NCT00426530
- Testing
- everolimus (RAD001)
- Where
- 6 sites in Belgium, France and 3 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Gastrointestinal Cancer, Metastatic
A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers
This study is open to adults with advanced colorectal cancer or with advanced pancreatic cancer. The study has 2 parts. In the first part, participants with colorectal cancer get a medicine called BI 905711 combined with…
- Trial name
- NCT05087992
- Testing
- BI 905711, FOLFIRI, Bevacizumab
- Where
- 5 sites in United States, Belgium and 3 more
- Volunteers
- 13 people
- Sponsor
- Boehringer Ingelheim
End Stage Renal Disease
Research Study Evaluating Cinacalcet for Patients With End Stage Renal Disease (ESRD)
The purpose of this study is to observe the effects of a treatment strategy that incorporates cinacalcet HCl into the management of secondary hyperparathyroidism (HPT) in subjects with ESRD receiving hemodialysis, on bio-intact…
- Trial name
- NCT00113945
- Testing
- Cinacalcet
- Volunteers
- 360 people
- Sponsor
- Amgen
Patients With Non-Small Cell Lung Cancer
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance.
- Trial name
- ARTEMIA (NCT06472245)
- Testing
- OSE2101, Docetaxel, NGS HLAA2 assay
- Where
- 207 sites in United States, Belgium and 12 more
- Volunteers
- 363 people
- Sponsor
- OSE Immunotherapeutics
Brain Metastases, Lung Cancer Metastatic
Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer
The study will use an Ommaya reservoir that drains into brain metastases to deliver activated, autolous dendritic cells to the tumor lesion, for patients who are 18 - 75 years old who have brain metastases from either lung cancer…
- Conditions
- Brain Metastases, Lung Cancer Metastatic, Breast Cancer Metastatic
- Trial name
- NCT03638765
- Testing
- DCVax-Direct
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Northwest Biotherapeutics
Macular Degeneration
Visudyne® in Occult (VIO)
The purpose of this study is to demonstrate that Visudyne therapy in patients who have occult with no classic subfoveal choroidal neovascularization (CNV) lesions will, with an acceptable safety profile, significantly reduce the…
- Trial name
- NCT00121407
- Testing
- Visudyne for injection
- Volunteers
- 364 people
- Sponsor
- QLT Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.